Journal
JOURNAL OF CLINICAL PHARMACY AND THERAPEUTICS
Volume 45, Issue 3, Pages 573-576Publisher
WILEY-HINDAWI
DOI: 10.1111/jcpt.13089
Keywords
drug-related side effects and adverse reactions; leishmaniasis; meglumine antimoniate; pharmacovigilance
Categories
Ask authors/readers for more resources
What is known and objectives Adverse drug reactions (ADR) related to the treatment of visceral leishmaniasis (VL) can cause severe clinical complications. We report a case series of ADR in hospitalized VL patients on meglumine antimoniate (MA). Case description Seven cases of patients taking MA had at least one objective evidence for suspected ADR, including electrocardiographic, laboratory or clinical alteration. What is new and conclusion Meglumine antimoniate is highly toxic. Adherence to treatment guidelines is important. Pharmacists working in multidisciplinary teams may contribute to early detection and management of MA therapy-related ADR.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available